Skip to main content

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Phase 2/3 Adaptive Study of VX-147 in Adults and Adolescents With APOL1- Mediated Proteinuric Kidney Disease

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Phase 2/3 Adaptive Study of VX-147 in Adults and Adolescents With APOL1- Mediated Proteinuric Kidney Disease

Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

First-in-human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS)

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about First-in-human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS)

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 31
  • Page 32
  • Page 33
  • Page 34
  • Page 35
  • Page 36
  • Page 37
  • Page 38
  • Page 39
  • …
  • Next page Next
  • Last page Last
Subscribe to